These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38539409)

  • 1. Off-Label Yellow Fever and Hepatitis A Vaccination in Traveling Children.
    Muruzábal C; Vicente L; Escolano Taravillo L; Bravo Queipo de Llano B; Calvo C; García López Hortelano M
    Children (Basel); 2024 Mar; 11(3):. PubMed ID: 38539409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccination status and safety in hemodialysis patients.
    Facincani T; Guimarães MN; De Sousa Dos Santos S
    Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
    Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
    Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study.
    Koehl B; Aupiais C; Schinckel N; Mornand P; Odièvre MH; Niakate A; Brousse V; Ithier G; Missud F; Holvoet L; Benkerrou M; Sorge F; Faye A
    J Travel Med; 2021 Apr; 28(3):. PubMed ID: 33550421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
    Koren MA; Lin L; Eckels KH; De La Barrera R; Dussupt V; Donofrio G; Sondergaard EL; Mills KT; Robb ML; Lee C; Adedeji O; Keiser PB; Curley JM; Copeland NK; Crowell TA; Hutter JN; Hamer MJ; Valencia-Ruiz A; Darden J; Peel S; Amare MF; Mebrahtu T; Costanzo M; Krebs SJ; Gromowski GD; Jarman RG; Thomas SJ; Michael NL; Modjarrad K
    Lancet Infect Dis; 2023 Oct; 23(10):1175-1185. PubMed ID: 37390836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.
    Dumas R; Forrat R; Lang J; Farinelli T; Loutan L
    Adv Ther; 1997; 14(4):160-7. PubMed ID: 10174195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
    Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
    BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylaxis from yellow fever vaccine.
    Kelso JM; Mootrey GT; Tsai TF
    J Allergy Clin Immunol; 1999 Apr; 103(4):698-701. PubMed ID: 10200022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of anaphylaxis to YF-VAX® yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.
    McClenathan BM; Taylor JN; Housel LA; Ryan M
    J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38051650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.